Publicaties

Dit zijn mijn peer-reviewed publicaties:

  1. van Miert JHA, Hop H, Borjas-Howard JF, Meijer K. A milder clinical course for severe hemophilia B: a true or biased effect? Haematologica. 2016 Jun;101(6):e266.
  2. van Miert JHA, Meijer K. Re: Quality of warfarin therapy and risk of stroke, bleeding, and mortality among patients with atrial fibrillation. Pharmacoepidemiology and Drug Safety. 2018 Feb;27(2):243–243.
  3. van Miert JHA, Bos S, Veeger NJGM, Meijer K. Clinical usefulness of the SAMe-TT2R2 score: A systematic review and simulation meta-analysis. Nagler M, editor. PLOS ONE. 2018 Mar 13;13(3):e0194208.
  4. van Miert J, Piersma-Wichers M, Meijer K. Directe orale antistollingsmiddelen ook in Nederland een goede keus. Huisarts en wetenschap. 2019 Aug 24;62(8):54–54.
  5. van Miert JHA, Veeger NJGM, Meijer K. An easy-to-use tool to flag patients at risk of poor INR control: A streak of subtherapeutic INRs. Thrombosis Research. 2019 Sep;181(June):46–51.
  6. van Miert JHA, Kooistra HAM, Veeger NJGM, Westerterp A, Piersma-Wichers M, Meijer K. Choosing between continuing vitamin K antagonists (VKA) or switching to a direct oral anticoagulant in currently well-controlled patients on VKA for atrial fibrillation: a randomised controlled trial (GAInN). British Journal of Haematology. 2019 Aug 6;186(3):e21–3.
  7. van Miert JHA, Kooistra HAM, Veeger NJGM, Westerterp A, Piersma-Wichers M, Meijer K. Quality of life after switching from well-controlled vitamin K antagonist to direct oral anticoagulant: Little to GAInN. Thrombosis Research. 2020 Jun;190:69–75.
  8. van Miert JHA, Veeger NJGM, Meijer K. Is the time in therapeutic range on coumarins predicted by previous time in therapeutic range? Research and Practice in Thrombosis and Haemostasis. 2020 May 30;4(4):604–9.
  9. van Miert JHA, Veeger NJGM, ten Cate-Hoek AJ, Piersma-Wichers M, Meijer K. Effect of switching from acenocoumarol to phenprocoumon on time in therapeutic range and INR variability: A cohort study. Barboza MA, editor. PLOS ONE. 2020 Jul 10;15(7):e0235639.
  10. Borjas-Howard JF, Bhoelan S, van Miert J, Eck R, Kooistra HAM, Meijer K, et al. Beware overestimation of thrombosis in ICU: Mortality is not the only competing risk! Thrombosis Research. 2020 Sep;193:78.
  11. Piersma-Wichers M, van Miert JHA, Veeger NJGM, Kooistra HAM, Meijer K. More precise dosing of acenocoumarol for better control in patients aged above 80 years, a randomised controlled pilot study. Thrombosis Research. 2020 Oct.
  12. van Miert JHA, Piersma-Wichers M, Meijer K. Overstappen van acenocoumarol naar fenprocoumon – Stap richting gepersonaliseerde antistolling?. Nederlands Tijdschrift voor Geneeskunde 2021;165:D5533.